RecruitingPhase 2NCT07400302
Rare condition
Malignant melanoma of the mucosa
10
studies recruiting now
as of 7 Sept 2026
54
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
20 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT04318717
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
RecruitingPhase 1NCT07600476
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
RecruitingPhase 1NCT05098210
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
RecruitingPhase 2NCT05384496
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 10 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Malignant melanoma of the mucosa study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Malignant melanoma of the mucosa
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).